Trade

Caplin Point Laboratories share price

Balanced risk
  • 32%Low risk
  • 32%Moderate risk
  • 32%Balanced risk
  • 32%High risk
  • 32%Extreme risk
  • ₹2,023.05(9.77%)
    May 14, 2026 15:55:01 PM IST
    • NSE
    • BSE
  • Vol : 2.43 M (NSE + BSE)
    Last 20 day avg : 209.58 K

Caplin Point Laboratories is trading 9.77% upper at Rs 2,023.05 as compared to its last closing price. Caplin Point Laboratories has been trading in the price range of 2,057.10 & 1,806.00. Caplin Point Laboratories has given 10.10% in this year & 8.42% in the last 5 days. Caplin Point Laboratories has TTM P/E ratio 22.77 as compared to the sector P/E of 24.31.There are 2 analysts who have initiated coverage on Caplin Point Laboratories. There are 1 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 163.88 Crores in its last quarter.Listed peers of Caplin Point Laboratories include Torrent Pharmaceuticals (2.85%), Dr Reddy's Laboratories (2.98%), Cipla (8.05%).The Mutual Fund holding in Caplin Point Laboratories was at 2.02% in 31 Mar 2026. The MF holding has increased from the last quarter. The FII holding in Caplin Point Laboratories was at 6.15% in 31 Mar 2026. The FII holding has decreased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Loading...
Key Metrics

Updated on May 15, 2026, 02:39 AM UTC

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.83
    Low volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.00
    Lower than industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.16
    Lower than industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    4.91
    Higher than historical values
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    22.88
    Higher than historical values
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    1.07
    Indicates Fair Valuation
Price range
Day Range
Lowest
1,806.00
Highest
2,057.10
52 week range
Lowest
1,502.45
Highest
2,396.95
Caplin Point Laboratories News
Caplin Point Laboratories Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Torrent Pharmaceuticals
Bullish
4,417.652.851,48,470.3467.3217.10.8317.62
Dr Reddy's Laboratories
Bullish
1,302.802.981,08,734.0218.633.140.632.34
Cipla
Moderately Bullish
1,434.008.051,15,557.4022.953.870.870.81
Sun Pharmaceutical Industries
Bullish
1,863.002.124,46,985.5736.245.770.920.50
Divi's Laboratories
Bullish
6,947.002.281,84,317.9078.6111.520.460.01
Mutual Fund Ownership
View all
Samco Flexi Cap Fund Regular Growth
1/5
  • Amount Invested (Cr.) 29.93
  • % of AUM 6.51
Samco ELSS Tax Saver Fund Regular Growth
NA
  • Amount Invested (Cr.) 3.66
  • % of AUM 3.00
UTI Healthcare Fund Regular Plan Growth
NA
  • Amount Invested (Cr.) 26.84
  • % of AUM 2.53
UTI Small Cap Fund Regular Growth
2/5
  • Amount Invested (Cr.) 75.45
  • % of AUM 1.67
DSP Nifty Smallcap250 Quality 50 Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 3.92
  • % of AUM 1.53
Caplin Point Laboratories Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2026-05-14Audited Results & Interim Dividend
2026-02-05Quarterly Results
2025-11-06Quarterly Results
2025-11-05Quarterly Results
2025-08-07Quarterly Results, Final Dividend & A.G.M.
About the company Caplin Point Laboratories
  • IndustryBiotechnology & Drugs
  • ISININE475E01026
  • BSE Code524742
  • NSE CodeCAPLIPOINT
Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. In the Regulated Markets, its products include liquid & lyophilized vials, pre-filled syringes, three-pc ophthalmic droppers and pre-mix bags. In the Emerging Markets, its products include tablets, dry syrups - bottles, soft gels, capsules, suppositories, liquid syrups - bottles, liquid injectables in ampoules & vials, lyophilized vials, prefilled syringes (PFS), and emulsion injection in ampoules & vials.
  • Management Info
  • Ashok PartheebanVice Chairman of the Board
  • Vivek PartheebanVice Chairman of the Board
  • D. MuralidharanChief Financial Officer
  • G. VenkatramCompliance Officer, General Counsel, Company Secretary
  • Sridhar GanesanManaging Director, Executive Director
Caplin Point Laboratories Share Price FAQs

Caplin Point Laboratories is trading at 2023.05 as on Thu May 14 2026 10:25:01. This is 9.77% upper as compared to its previous closing price of 1843.00.

The market capitalization of Caplin Point Laboratories is 15360.88 Cr as on Thu May 14 2026 10:25:01.

The average broker rating on Caplin Point Laboratories is Strong Buy. The breakup of analyst rating is given below -

  • 1 analysts have given a strong buy rating
  • 1 analysts have given a buy rating
  • 0.00 analysts have given a hold rating
  • 0.00 analysts have given a sell rating
  • 0.00 analysts have given a strong sell rating

The 52 wk high for Caplin Point Laboratories is 2396.95 whereas the 52 wk low is 1502.45

Caplin Point Laboratories can be analyzed on the following key metrics -

  • TTM P/E: 22.77
  • Sector P/E: 24.31
  • Dividend Yield: 0.35%
  • D/E ratio: -

Caplin Point Laboratories reported a net profit of 536.31 Cr in 2025.

The Mutual Fund Shareholding was 2.02% at the end of 31 Mar 2026.

Quick Links
EQUITY QUICK LINKS
Caplin Point Laboratories QUICK LINKS
FROM MARKETS
RELATED LINKS
Quarterly Results
Home/Market/Market Stats/  Caplin Point Laboratories share price
✕

Wait for it…

Log in to our website to save your bookmarks. It'll just take a moment.

✕

Wait for it…

Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.